SCHEMBL6775374

SCHEMBL6775374

CCOC(=O)C(C)(C)SC/C=C/c1ccc(Cc2nc(-c3ccc(N(C)C)cc3)oc2C)o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.38
TARBP2 Q15633 5/20 0.34
PDCD4 Q53EL6 1/20 0.33
PPARG P37231 4/20 0.33
PPARA Q07869 4/20 0.33
PPARD Q03181 1/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 3/20 0.33
ALOX15 P16050 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 2/20 0.32
HPGD P15428 2/20 0.32
SIRT2 Q8IXJ6 3/20 0.32
TSHR P16473 1/20 0.32
XBP1 P17861 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SIRT1 Q96EB6 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6775375 1.00 HSD17B10 (0.38) HSD17B10TARBP2PDCD4PPARGPPARA
SCHEMBL6780504 0.90 KDM4E (0.36) PPARGPPARAPPARDKDM4ENPC1
SCHEMBL6780496 0.90 KDM4E (0.36) PPARGPPARAPPARDKDM4ENPC1
SCHEMBL6781787 0.84 HPGD (0.39) HSD17B10PPARGPPARAKDM4EALDH1A1
SCHEMBL6781783 0.84 HPGD (0.39) HSD17B10PPARGPPARAKDM4EALDH1A1
SCHEMBL6774862 0.83 LATS1 (0.31)
SCHEMBL6774859 0.83 LATS1 (0.31)
SCHEMBL6776054 0.81 KDM4E (0.39) HSD17B10PPARGPPARAKDM4EALDH1A1
SCHEMBL6776046 0.81 KDM4E (0.39) HSD17B10PPARGPPARAKDM4EALDH1A1
SCHEMBL7052376 0.81 HSD17B10 (0.38) HSD17B10TARBP2PDCD4PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2003-12-04 US claimed
US-6589969-B1 A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive ONO PHARMACEUTICAL CO., LTD. (JP) 2003-07-08 US claimed
EP-1122255-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP claimed
US-6821994-B2 A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR REGULATOR, AN OXAZOL-4-YL-METHYLFURAN-2-YL-2-PROPENYLTHIO- OR SULFONYL- OR SULFINYL-ACETIC ACID OR METHYL ESTER ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-23 US disclosed
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2003-12-04 US disclosed
US-6589969-B1 A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive ONO PHARMACEUTICAL CO., LTD. (JP) 2003-07-08 US disclosed
EP-1122255-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD HSD17B10 111/4885TARBP2 3393/4885PDCD4 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.